Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYAD
CUSIPN/A
Phone321-039-4100
Debt
Debt-to-Equity Ratio0.01
Current Ratio6.61
Quick Ratio4.58
Price-To-Earnings
Trailing P/E Ratio-7.80
Forward P/E Ratio-7.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$4 million
Price / Sales67.88
Cash FlowN/A
Price / CashN/A
Book Value$5.44 per share
Price / Book5.06
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees87
Outstanding Shares9,870,000
Market Cap$272.48 million
CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions
What is CELYAD SA/ADR's stock symbol?
CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD."
What price target have analysts set for CYAD?
4 Wall Street analysts have issued 1 year price objectives for CELYAD SA/ADR's stock. Their predictions range from $44.00 to $74.00. On average, they anticipate CELYAD SA/ADR's stock price to reach $53.00 in the next year. This suggests a possible upside of 92.7% from the stock's current price. View Analyst Price Targets for CELYAD SA/ADR.
What is the consensus analysts' recommendation for CELYAD SA/ADR?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELYAD SA/ADR.
Who are some of CELYAD SA/ADR's key competitors?
Some companies that are related to CELYAD SA/ADR include Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Rhythm Pharmaceuticals (RYTM), Vanda Pharmaceuticals (VNDA), Eagle Pharmaceuticals (EGRX), Apellis Pharmaceuticals (APLS), Geron (GERN), Dicerna Pharmaceuticals (DRNA), MacroGenics (MGNX), CannTrust (CNTTF), Aptinyx (APTX), Rocket Pharmaceuticals (RCKT), Revance Therapeutics (RVNC), Assembly Biosciences (ASMB) and Cara Therapeutics (CARA).
Who are CELYAD SA/ADR's key executives?
CELYAD SA/ADR's management team includes the folowing people:
- Mr. Michel E. Lussier, Co-Founder & Chairman (Age 62)
- Dr. Christian Homsy M.D., MBA, CEO & Exec. Director (Age 60)
- Mr. Patrick Jeanmart, Chief Financial Officer & Investor Relations (Age 46)
- Dr. Jean-Pierre Latere, Chief Operating Officer (Age 43)
- Mr. Philippe Dechamps, Chief Legal Officer (Age 48)
When did CELYAD SA/ADR IPO?
(CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.
Has CELYAD SA/ADR been receiving favorable news coverage?
News coverage about CYAD stock has been trending somewhat positive on Friday, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CELYAD SA/ADR earned a daily sentiment score of 0.18 on Accern's scale. They also assigned news articles about the company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for CELYAD SA/ADR.
Who are CELYAD SA/ADR's major shareholders?
CELYAD SA/ADR's stock is owned by a number of of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (6.12%), Stanley Laman Group Ltd. (0.39%) and Millennium Management LLC (0.19%).
Which institutional investors are buying CELYAD SA/ADR stock?
CYAD stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Stanley Laman Group Ltd. and Millennium Management LLC.
How do I buy shares of CELYAD SA/ADR?
Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELYAD SA/ADR's stock price today?
One share of CYAD stock can currently be purchased for approximately $27.51.
How big of a company is CELYAD SA/ADR?
CELYAD SA/ADR has a market capitalization of $272.48 million and generates $4 million in revenue each year. The company earns $-63,740,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. CELYAD SA/ADR employs 87 workers across the globe.
How can I contact CELYAD SA/ADR?
CELYAD SA/ADR's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at 321-039-4100.
MarketBeat Community Rating for CELYAD SA/ADR (NASDAQ CYAD)
MarketBeat's community ratings are surveys of what our community members think about CELYAD SA/ADR and other stocks. Vote "Outperform" if you believe CYAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
